GO:0046849 bone remodeling: The Continuous Turnover Cycle, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046849 bone remodeling is the continuous turnover of bone matrix and mineral, involving an initial increase in osteoclastic resorption followed by reactive osteoblastic formation at discrete foci in the adult skeleton.
• The process ensures mechanical integrity of the skeleton throughout life and plays a critical role in calcium homeostasis.
• An imbalance between bone resorption and formation underlies metabolic bone diseases such as osteoporosis.
• Key genes and proteins include RANKL (TNFSF11), OPG (TNFRSF11B), RANK (TNFRSF11A), M-CSF (CSF1), RUNX2, SP7 (Osterix), SOST (Sclerostin), and PTH.
• Bone remodeling is regulated by systemic hormones (PTH, vitamin D, calcitonin, estrogen) and local factors (cytokines, growth factors, Wnt signaling).
• Research methods include histomorphometry, biochemical markers (CTX, P1NP), micro-CT, and CRISPR-based gene editing to model bone diseases.
Description
Bone remodeling (GO:0046849) is a fundamental biological process that continuously renews the adult skeleton. It involves the coordinated action of bone-resorbing osteoclasts and bone-forming osteoblasts, which work in sequence to replace discrete packets of old bone with new bone. This process is essential for maintaining mechanical integrity, repairing microdamage, and regulating calcium homeostasis. Dysregulation of bone remodeling is central to the pathogenesis of osteoporosis, Paget's disease, and other metabolic bone disorders. Understanding the cellular and molecular mechanisms of bone remodeling is therefore critical for developing targeted therapies and for interpreting genetic and pharmacological studies. Recent advances in CRISPR gene editing have enabled precise modeling of bone remodeling-related genes, accelerating the discovery of novel therapeutic targets.
bone remodeling At A Glance
| GO ID | GO:0046849 |
|---|---|
| GO term | bone remodeling |
| Ontology | biological_process |
| Synonym | bone remodelling |
| Major function | Continuous turnover of bone matrix and mineral; maintains skeletal integrity and calcium homeostasis |
| Cellular players | Osteoclasts (resorption), osteoblasts (formation), osteocytes (regulation) |
| Key regulators | RANKL, OPG, M-CSF, PTH, vitamin D, estrogen, Wnt signaling |
| Disease relevance | Osteoporosis, Paget's disease, rheumatoid arthritis, bone metastases |
| Research methods | Histomorphometry, biochemical markers, micro-CT, CRISPR gene editing |
What Is GO:0046849?
According to the Gene Ontology, GO:0046849 bone remodeling is defined as the continuous turnover of bone matrix and mineral that involves first an increase in resorption (osteoclastic activity) and later reactive bone formation (osteoblastic activity). This process takes place in the adult skeleton at discrete foci, ensures the mechanical integrity of the skeleton throughout life, and plays an important role in calcium homeostasis. An imbalance in the regulation of bone resorption and bone formation results in many metabolic bone diseases, such as osteoporosis.
Why Is bone remodeling Important in Cell Biology?
Bone remodeling is vital for skeletal health throughout life. It allows the skeleton to adapt to mechanical stress, repair microdamage, and maintain calcium homeostasis. Disruption of the balanced coupling between bone resorption and formation leads to metabolic bone diseases, most notably osteoporosis, which affects millions worldwide. Understanding the molecular regulation of bone remodeling is essential for identifying therapeutic targets and for developing interventions that can restore skeletal integrity.
• Maintains mechanical integrity of the skeleton by replacing old or damaged bone.
• Regulates calcium and phosphate homeostasis, critical for neuromuscular and cardiac function.
• Provides a reservoir for hematopoietic stem cell niches and supports hematopoiesis.
• Dysregulation causes osteoporosis, characterized by low bone mass and increased fracture risk.
• Implicated in Paget's disease of bone, characterized by abnormal osteoclast activity.
• Plays a role in inflammatory joint diseases such as rheumatoid arthritis.
• Contributes to bone metastasis in cancers, where tumor cells disrupt the remodeling cycle.
• Serves as a target for anabolic and antiresorptive therapies (e.g., bisphosphonates, PTH analogs).
• Aging leads to imbalanced remodeling, with increased resorption and decreased formation.
• Genetic studies of remodeling genes inform personalized medicine for skeletal disorders.
What Happens During bone remodeling?
Initiation and Osteoclast Activation
In simple terms: Bone remodeling starts when old bone is broken down by specialized cells called osteoclasts.
Bone remodeling is initiated at discrete foci in response to microdamage, mechanical strain, or systemic signals. Osteoclast precursors are recruited and differentiate into mature osteoclasts under the influence of M-CSF (CSF1) and RANKL (TNFSF11), which bind to their receptors on osteoclast precursors. This activation leads to the formation of a sealing zone and a ruffled border, where osteoclasts secrete protons and proteolytic enzymes (e.g., cathepsin K, MMP-9) to dissolve bone mineral and degrade the organic matrix. The resorption phase lasts approximately 2-4 weeks and creates a resorption pit.
Resorption-to-Formation Coupling
In simple terms: After bone is broken down, signals are sent to trigger new bone formation.
The transition from resorption to formation is tightly coupled. Factors released from the bone matrix during resorption (e.g., IGF-1, TGF-beta) and factors secreted by osteoclasts (e.g., Wnt ligands, S1P) stimulate osteoblast recruitment and differentiation. Osteoblasts are derived from mesenchymal stem cells and require RUNX2 and SP7 (Osterix) for differentiation. This coupling ensures that the amount of bone removed is replaced by an equal amount of new bone under normal conditions.
Osteoblast Differentiation and Bone Formation
In simple terms: New bone is built by osteoblasts, which produce and mineralize the bone matrix.
Osteoblasts synthesize and secrete type I collagen and other matrix proteins, which subsequently mineralize through the deposition of hydroxyapatite. Osteoblast differentiation is regulated by canonical Wnt signaling, which stabilizes beta-catenin and promotes expression of RUNX2 and SP7. Mature osteoblasts also express RANKL and OPG, thereby regulating osteoclastogenesis and maintaining the balance between resorption and formation. After completing matrix deposition, some osteoblasts become osteocytes embedded in the matrix, while others undergo apoptosis or become lining cells.
Termination and Quiescence
In simple terms: Once new bone is formed, the remodeling cycle stops and the bone returns to a resting state.
The remodeling cycle concludes when the resorbed area is completely filled with new bone. Osteocytes, the most abundant bone cells, act as mechanosensors and secrete sclerostin (SOST), which inhibits Wnt signaling and thereby suppresses bone formation. This negative feedback prevents excessive bone formation and maintains skeletal homeostasis. The entire cycle takes approximately 3-6 months in humans, with resorption and formation phases tightly regulated by systemic and local factors.
Key Genes Involved in GO:0046849 bone remodeling
The following genes and proteins are central to the regulation and execution of bone remodeling, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFSF11 (RANKL) | Key cytokine that induces osteoclast differentiation and activation | Target for antiresorptive therapy (denosumab); knockout models show osteopetrosis |
| TNFRSF11B (OPG) | Decoy receptor for RANKL, inhibits osteoclastogenesis | Overexpression causes osteopetrosis; knockout leads to osteoporosis |
| TNFRSF11A (RANK) | Receptor for RANKL on osteoclast precursors | Mutations cause osteopetrosis; essential for osteoclast differentiation |
| CSF1 (M-CSF) | Cytokine required for osteoclast precursor proliferation and survival | Knockout mice lack osteoclasts and develop osteopetrosis |
| RUNX2 | Master transcription factor for osteoblast differentiation | Haploinsufficiency causes cleidocranial dysplasia |
| SP7 (Osterix) | Transcription factor essential for osteoblast differentiation and bone formation | Knockout mice lack bone formation |
| SOST (Sclerostin) | Secreted by osteocytes, inhibits Wnt signaling and bone formation | Inhibition increases bone mass; mutations cause sclerosteosis |
| CTNNB1 (Beta-catenin) | Central mediator of canonical Wnt signaling in osteoblasts | Conditional knockout reduces bone mass; activating mutations increase bone mass |
| PTH | Systemic hormone that regulates calcium and bone remodeling | Intermittent administration is anabolic; continuous is catabolic |
| VDR | Vitamin D receptor, mediates effects of vitamin D on bone and calcium | Polymorphisms associated with bone mineral density |
| ESR1 | Estrogen receptor alpha, mediates estrogen effects on bone | Knockout mice exhibit increased bone resorption and osteoporosis |
| CTSK (Cathepsin K) | Protease secreted by osteoclasts to degrade bone collagen | Inhibitors are used for osteoporosis; mutations cause pycnodysostosis |
| ACP5 (TRAP) | Tartrate-resistant acid phosphatase, marker of osteoclast activity | Used as a serum marker for bone resorption |
| MMP9 | Matrix metalloproteinase secreted by osteoclasts for matrix degradation | Knockout mice show impaired osteoclast migration |
| IGF1 | Growth factor released from bone matrix, stimulates osteoblast function | Important for coupling resorption to formation |
| TGFB1 | Growth factor released during resorption, regulates osteoblast recruitment | Knockout mice show impaired bone formation |
| BGLAP (Osteocalcin) | Most abundant non-collagenous protein in bone, marker of osteoblast activity | Serum osteocalcin used as bone formation marker |
| ALPL (ALP) | Alkaline phosphatase, enzyme involved in bone mineralization | Serum ALP used as bone formation marker |
How Is bone remodeling Regulated?
Bone remodeling is regulated by a complex interplay of systemic hormones and local factors. Parathyroid hormone (PTH) and vitamin D regulate calcium homeostasis and bone turnover; intermittent PTH administration is anabolic, while continuous exposure is catabolic. Estrogen deficiency after menopause leads to increased osteoclast activity and bone loss, primarily through increased RANKL and decreased OPG. Canonical Wnt signaling promotes osteoblast differentiation and bone formation, and its inhibition by sclerostin (SOST) reduces bone mass. Local factors such as IGF-1, TGF-beta, and prostaglandins couple resorption to formation. Additionally, metabolic pathways including mTOR and the integrated stress response (ISR) have been implicated in skeletal cell fate and function.
bone remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFSF11 (RANKL) | Osteoporosis, rheumatoid arthritis | Knockout mice (osteopetrosis), overexpression (bone loss) |
| TNFRSF11B (OPG) | Osteoporosis, Paget's disease | Transgenic overexpression (osteopetrosis), knockout (osteoporosis) |
| SOST | Sclerosteosis, Van Buchem disease | Knockout mice (high bone mass), overexpression (osteopenia) |
| CTSK | Pycnodysostosis, osteoporosis | Knockout mice (osteopetrosis), point mutation (enzyme deficiency) |
| ESR1 | Postmenopausal osteoporosis | Knockout mice (bone loss), knock-in for human mutations |
Osteoporosis
Osteoporosis is the most common metabolic bone disease, characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk. It results from an imbalance in bone remodeling, with resorption exceeding formation. Postmenopausal osteoporosis is driven by estrogen deficiency, which increases RANKL and decreases OPG, promoting osteoclastogenesis. Therapeutic strategies include antiresorptives (bisphosphonates, denosumab) and anabolics (teriparatide, romosozumab).
Paget's Disease of Bone
Paget's disease is characterized by focal areas of excessive bone resorption followed by disorganized bone formation, leading to bone pain, deformity, and fractures. It is often caused by mutations in SQSTM1 (p62) and other genes affecting osteoclast function. The remodeling cycle is accelerated but uncoupled, resulting in structurally abnormal bone.
Rheumatoid Arthritis
In rheumatoid arthritis, chronic inflammation leads to increased osteoclastogenesis and bone erosion. Proinflammatory cytokines such as TNF-alpha and IL-6 stimulate RANKL expression, tipping the balance toward resorption. Targeting RANKL with denosumab has been explored to prevent joint destruction.
Bone Metastasis
Tumor cells that metastasize to bone can disrupt normal bone remodeling, leading to osteolytic or osteoblastic lesions. They secrete factors such as PTHrP and IL-6 that stimulate osteoclasts, creating a vicious cycle of bone destruction and tumor growth. Understanding the remodeling process is crucial for developing therapies to prevent skeletal-related events.
From bone remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate osteoclast differentiation? | Knockout of gene X in osteoclast precursors (e.g., RAW264.7 cells) followed by RANKL stimulation |
| Does a point mutation in gene Y affect osteoblast function? | Point-mutation knock-in in mesenchymal stem cells or mice |
| Does overexpression of gene Z increase bone mass? | Transgenic overexpression in osteoblasts (e.g., Col1a1 promoter) |
| Does a tag affect protein localization in bone cells? | Tagged knock-in (e.g., GFP) in osteoblasts or osteocytes |
| Does gene W affect bone remodeling in vivo? | Conditional knockout in osteoblasts or osteoclasts using Cre-lox system |
| Can CRISPR library screening identify novel regulators of osteoclastogenesis? | Pooled CRISPR knockout library in osteoclast precursor cells followed by RANKL treatment and sequencing |
How to Study the bone remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Histomorphometry | Dynamic bone formation and resorption parameters | Assessment of bone remodeling in animal models |
| Serum biomarkers (P1NP, CTX) | Bone formation and resorption rates | Clinical monitoring of osteoporosis treatment |
| Micro-CT | Bone microarchitecture (trabecular and cortical) | Evaluation of bone mass in knockout/transgenic mice |
| DXA | Bone mineral density | Diagnosis of osteoporosis in humans |
| RNA-seq | Transcriptomic profile of bone cells | Identification of differentially expressed genes during remodeling |
| CRISPR knockout screening | Functional gene essentiality in bone cells | Discovery of novel regulators of osteoclast/osteoblast differentiation |
| Proteomics | Protein expression and post-translational modifications | Characterization of bone matrix proteins and signaling |
| Immunohistochemistry | Protein localization in bone tissue | Detection of osteoclast markers (TRAP) and osteoblast markers (osteocalcin) |
Histomorphometry
Histomorphometry is the gold standard for assessing bone remodeling in vivo. It involves labeling bone with fluorochromes (e.g., calcein) at two time points, followed by histological sectioning and quantification of dynamic parameters such as mineral apposition rate and bone formation rate. This method provides direct measurement of osteoblast and osteoclast activity on bone surfaces.
Biochemical Markers
Serum and urine markers of bone turnover are widely used in clinical and research settings. Bone formation markers include P1NP (procollagen type I N-terminal propeptide), osteocalcin, and bone-specific alkaline phosphatase. Bone resorption markers include CTX (C-terminal telopeptide of type I collagen) and NTX. These markers reflect the overall rate of bone remodeling and are useful for monitoring treatment response.
Imaging Techniques
Dual-energy X-ray absorptiometry (DXA) measures bone mineral density (BMD) and is the clinical standard for diagnosing osteoporosis. Micro-computed tomography (micro-CT) provides high-resolution 3D images of bone microarchitecture in animal models, allowing quantification of trabecular and cortical parameters. These imaging methods are essential for evaluating the effects of genetic manipulations on bone mass and structure.
CRISPR Screening and Bioinformatics
Pooled CRISPR knockout screens combined with next-generation sequencing enable unbiased discovery of genes regulating bone remodeling. For example, a genome-wide screen in osteoclast precursors treated with RANKL can identify novel inhibitors or activators of osteoclastogenesis. Bioinformatics analysis of RNA-seq or single-cell RNA-seq data from bone cells can reveal gene expression networks and signaling pathways involved in remodeling.
How CRISPR Can Be Used to Study GO:0046849 bone remodeling
Knockout
CRISPR knockout is used to completely ablate a gene of interest to study its role in bone remodeling. For example, knockout of TNFSF11 (RANKL) in mice results in osteopetrosis due to lack of osteoclasts. In vitro, knockout of candidate genes in osteoclast precursors (e.g., RAW264.7) followed by RANKL stimulation can reveal essential regulators of osteoclastogenesis. EDITGENE provides custom knockout cell models for bone remodeling research.
Point Mutation
Point mutations can be introduced to model specific human genetic variants associated with bone diseases. For instance, knock-in of the p.Pro392Leu mutation in SQSTM1 (p62) recapitulates Paget's disease phenotypes in mice. Point mutations in CTSK cause pycnodysostosis, and modeling these mutations in cells helps understand enzyme dysfunction. EDITGENE offers precise point-mutation knock-in services.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags allows visualization and tracking of specific bone cell populations. For example, knock-in of GFP into the BGLAP locus enables isolation of osteoblasts by flow cytometry. Knock-in of human disease alleles into mouse models facilitates translational research. EDITGENE provides knock-in services for tagging, reporter, and disease allele models.
Overexpression
Overexpression of genes can be achieved by CRISPR-mediated knock-in of a strong promoter or by transgenic approaches. Overexpression of SOST in osteocytes leads to decreased bone mass, while overexpression of OPG causes osteopetrosis. Overexpression models are valuable for studying gain-of-function effects in bone remodeling. EDITGENE offers overexpression cell models using safe-harbor locus integration.
How EDITGENE Supports bone remodeling Research
Researchers studying bone remodeling-related genes often need to determine whether a candidate gene is causally involved in osteoclast or osteoblast differentiation, bone mass regulation, or disease pathogenesis. CRISPR-based gene editing provides a powerful approach to manipulate genes with precision, enabling loss-of-function, gain-of-function, and disease-modeling studies in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for bone remodeling research.
Frequently Asked Questions About bone remodeling
What is bone remodeling?
Bone remodeling is the continuous process by which old bone is removed by osteoclasts and replaced by new bone formed by osteoblasts. It maintains skeletal integrity and calcium homeostasis.
What genes are involved in bone remodeling?
Key genes include TNFSF11 (RANKL), TNFRSF11B (OPG), TNFRSF11A (RANK), CSF1 (M-CSF), RUNX2, SP7, SOST, and CTNNB1, among others.
What is the GO term for bone remodeling?
The Gene Ontology term for bone remodeling is GO:0046849, defined as the continuous turnover of bone matrix and mineral involving osteoclastic resorption followed by osteoblastic formation.
How is bone remodeling regulated?
Bone remodeling is regulated by systemic hormones (PTH, vitamin D, estrogen) and local factors (RANKL, OPG, Wnt signaling, cytokines) that control osteoclast and osteoblast activity.
What diseases are associated with abnormal bone remodeling?
Abnormal bone remodeling is associated with osteoporosis, Paget's disease of bone, rheumatoid arthritis, and bone metastasis.
What are the stages of bone remodeling?
The stages are initiation/osteoclast activation, resorption, reversal, osteoblast differentiation and bone formation, and termination/quiescence.
How can CRISPR be used to study bone remodeling?
CRISPR can create knockout, point mutation, knock-in, and overexpression models in bone cells to study gene function and model human diseases.
What are common markers of bone remodeling?
Common markers include P1NP and osteocalcin for bone formation, and CTX and NTX for bone resorption.
What is the role of osteocytes in bone remodeling?
Osteocytes are mechanosensory cells that regulate bone remodeling by secreting sclerostin (SOST) and RANKL, thereby controlling osteoblast and osteoclast activity.
How does estrogen affect bone remodeling?
Estrogen inhibits osteoclastogenesis by decreasing RANKL and increasing OPG production. Estrogen deficiency after menopause leads to increased bone resorption and osteoporosis.
Conclusion
Bone remodeling (GO:0046849) is a dynamic and tightly regulated process essential for skeletal health. The coordinated actions of osteoclasts and osteoblasts maintain bone mass and calcium homeostasis, and their dysregulation leads to prevalent diseases such as osteoporosis. Advances in CRISPR gene editing and high-throughput screening are accelerating the discovery of novel regulators and therapeutic targets in bone remodeling. Continued research using precise genetic models will further elucidate the molecular mechanisms and translate findings into clinical benefits.
References
- 1. Kenkre JS et al.. 2018. The bone remodelling cycle.. Ann Clin Biochem 55(3):308-327 PMID: 29368538
- 2. Katsimbri P. 2017. The biology of normal bone remodelling.. Eur J Cancer Care (Engl) 26(6) PMID: 28786518
- 3. Ramirez-GarciaLuna JL et al.. 2022. Enhanced Bone Remodeling After Fracture Priming.. Calcif Tissue Int 110(3):349-366 PMID: 34668029
- 5. Xiao W et al.. 2016. Cellular and Molecular Aspects of Bone Remodeling.. Front Oral Biol 18:9-16 PMID: 26599113
- 6. Stegen S et al.. 2024. Metabolic regulation of skeletal cell fate and function.. Nat Rev Endocrinol 20(7):399-413 PMID: 38499689
- 7. Laugier P et al.. 1998. [Bone remodeling: evaluation methods].. Rev Prat 48(11):1185-90 PMID: 9781169
